全文获取类型
收费全文 | 1733篇 |
免费 | 188篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 148篇 |
妇产科学 | 28篇 |
基础医学 | 225篇 |
口腔科学 | 91篇 |
临床医学 | 177篇 |
内科学 | 338篇 |
皮肤病学 | 60篇 |
神经病学 | 35篇 |
特种医学 | 191篇 |
外科学 | 276篇 |
综合类 | 38篇 |
预防医学 | 103篇 |
眼科学 | 43篇 |
药学 | 71篇 |
中国医学 | 2篇 |
肿瘤学 | 102篇 |
出版年
2023年 | 16篇 |
2022年 | 10篇 |
2021年 | 16篇 |
2020年 | 15篇 |
2019年 | 9篇 |
2018年 | 48篇 |
2017年 | 47篇 |
2016年 | 43篇 |
2015年 | 64篇 |
2014年 | 79篇 |
2013年 | 116篇 |
2012年 | 57篇 |
2011年 | 36篇 |
2010年 | 89篇 |
2009年 | 98篇 |
2008年 | 45篇 |
2007年 | 71篇 |
2006年 | 61篇 |
2005年 | 35篇 |
2004年 | 38篇 |
2003年 | 24篇 |
2002年 | 29篇 |
2001年 | 21篇 |
2000年 | 12篇 |
1999年 | 31篇 |
1998年 | 106篇 |
1997年 | 93篇 |
1996年 | 106篇 |
1995年 | 69篇 |
1994年 | 76篇 |
1993年 | 40篇 |
1992年 | 17篇 |
1991年 | 25篇 |
1990年 | 18篇 |
1989年 | 34篇 |
1988年 | 33篇 |
1987年 | 31篇 |
1986年 | 28篇 |
1985年 | 24篇 |
1984年 | 13篇 |
1983年 | 9篇 |
1982年 | 20篇 |
1981年 | 16篇 |
1980年 | 16篇 |
1979年 | 6篇 |
1978年 | 6篇 |
1977年 | 9篇 |
1976年 | 13篇 |
1975年 | 10篇 |
1922年 | 3篇 |
排序方式: 共有1949条查询结果,搜索用时 312 毫秒
1.
2.
P Avalos-Peralta† A Herrera† JJ Ríos-Martín‡ AM Pérez-Bernal† D Moreno-Ramírez† F Camacho† 《Journal of the European Academy of Dermatology and Venereology》2006,20(1):79-83
We report the case of a patient with a 13-year history of pemphigus vulgaris (PV) treated with immunosuppressive agents, prednisone and mycophenolate mofetil who had developed lesions of Kaposi's sarcoma (KS) on a sole plaque of PV that had been previously treated with intralesional injections of steroids. The lesions were surgically removed and polymerase chain reaction (PCR) demonstrated human herpesvirus-8 (HHV-8) DNA. There were neither recurrences nor later dissemination of KS following gradual decrease of the immunosuppressive therapy. We suggest that the treatment with intralesional steroids may have influenced the local reactivation of a latent infection of the virus, determining the appearance of this localized KS. 相似文献
3.
4.
5.
J. Duteil FA Rambert AM Pointeau P. Mangiameli and E. Assous 《Fundamental & clinical pharmacology》1991,5(8):695-708
The potential antidepressant effect of flerobuterol (dl-(fluoro-2 phenyl)-1 t-butylamino-2 ethanol), a new drug related to beta-adrenoceptor agonists, was evaluated and compared with imipramine and salbutamol using classical psychopharmacological tests in mice. Like imipramine and salbutamol, flerobuterol (0.5-32 mg kg-1, ip) fully prevented apomorphine (16 mg kg-1, sc)- and partly reversed reserpine- and oxotremorine-induced hypothermia. At higher doses (16-32 mg kg-1), flerobuterol enhanced the toxic effects of yohimbine. Unlike imipramine, flerobuterol and salbutamol did not reduce immobility duration in the behavioural despair test. Salbutamol and flerobuterol decreased locomotor activity. Flerobuterol did not induce mydriasis, did not prevent oxotremorine-induced tremors or salivary and lacrimal gland secretion and did not reduce reserpine-induced palpebral ptosis. Propranolol (8 mg kg-1, ip) but not alpha-methyl-paratyrosine (75 mg kg-1, ip) prevented the flerobuterol-induced antagonism of apomorphine-induced hypothermia. Our results suggest that flerobuterol demonstrates potential antidepressant activity, which could be related to beta-adrenoceptor activation in mice. 相似文献
6.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
7.
By oxygen concentration measurements (Oximeter Oxydig Dräger, Lübeck) in the EC 145 helicopter two oxygen transport and application systems were compared. The new liquid oxygen system (LOX) for the oxygen therapy was assessed in an application observation. For physical reasons fluid oxygen evaporates during the stand-by phase and an increased concentration (22.8% O2) in the exhaust valve of LOX arises. On the other hand a high oxygen concentration (22.7% O2) was measured in the operation mode of the conventional pressure flask gas system (GAS). No increased concentration could be measured within the helicopter cabin (HEMS, PAX) comparing both oxygen systems. For transport and application of oxygen with a very big reserve for the air dependent intensive transport the results show that LOX is a sure low pressure system (3.4 bar). 相似文献
8.
P Hildebrand U J Roblick R Keller M Kleemann L Mirow H-P Bruch 《Der Chirurg》2007,78(6):494, 496-494, 500
Minimizing the access trauma of surgical interventions is becoming an essential task in modern surgery in order to make the treatment more comfortable for the patient. Minimally invasive surgery has had a major impact on the improvement of surgical results over the last decade. This is why such surgery is often named as the third patient friendly revolution in surgery after the introduction of asepsis and anesthesia. Operations that caused a huge strain on the patients in the past and led to immense costs for society because of the patient's lost working time and extensive rehabilitation, have lost their fear thanks to this technique. The physical strain is lower, the cosmetic effect is considerable and the costs for society might be reduced due to the significantly shorter duration of convalescence.Despite its known advantages, which have been reported in numerous studies, minimally invasive surgery has recently gained increased interest because of the installation of new accounting systems as well as strict budgeting and restricted resources.Realistic cost-benefit analysis and objectified quality controls are needed in order to guarantee innovative and patient friendly basic approaches in medicine in the future. 相似文献
9.
Radiofrequency-ablation of unresectable primary and secondary liver tumors: results in 88 patients 总被引:5,自引:0,他引:5
Philipp Hildebrand Markus Kleemann Uwe J. Roblick Lutz Mirow Matthias Birth Thorsten Leibecke Hans-Peter Bruch 《Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie》2006,391(2):118-123
Background and aims Radiofrequency-ablation (RFA) is increasingly used for destruction of unresectable primary and secondary liver tumors. We
report our experience in the use of RFA for the management of unresectable hepatic malignancies.
Patients and methods Between February 2000 and December 2004 we have undertaken 120 RFA procedures to ablate 426 unresectable primary or metastatic
liver tumors in 88 patients. RFA was performed via laparotomy (n=68), laparoscopy (n=9) or a percutaneous approach (n=43). Primary liver cancer was treated in seven patients (8%) and metastatic liver tumors were treated in 81 patients (92%).
All patients were followed to assess complications, treatment response and recurrence of malignant disease.
Results Procedure-related complication rate was low (3.4%). During a mean follow-up of 21.2 months, 15 patients had local tumor progression
(17%), 21 patients (23,9%) had new malignant disease and 27 patients (30.7%) died from intervention-unrelated complications
of their malignant disease. Additional liver lesions were identified in 27 (35%) of 77 cases by intraoperative ultrasound.
Thirty-six patients received simultaneous resection and RFA.
Conclusion RFA is a safe, well-tolerated and effective treatment for patients with unresectable primary and secondary liver malignancies. 相似文献
10.